<div data-server-rendered="true" id="__nuxt"><div id="__layout"><div class="outer-container"><div class="content-container"> <div class="answer_container" style="min-height:calc(100vh - 54px);" data-v-0eba195e=""><div class="content_outer_container" data-v-0eba195e=""><div class="share_preview_container" data-v-0eba195e=""><div class="dialog_list" data-v-0eba195e=""><div class="dialog_item" data-v-0eba195e=""><div class="dialog_question fir_dialog_question" data-v-0eba195e=""><div class="question_con" data-v-0eba195e=""><h1 class="fir_question_content" data-v-0eba195e="">
                                    How did Verona Pharmaceuticals' expenses trend in Q4 2024?
                                </h1> <div class="user_slot" data-v-0eba195e=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/default_aime_user.ec532c9.png" alt="user" class="avatar" data-v-0eba195e=""> <span class="user_desction" data-v-0eba195e="">
                                        
                                        5/9/2025 00:10am
                                    </span></div></div></div> <div class="seo-text-answer" data-v-0eba195e="">Verona Pharmaceuticals' expenses in Q4 2024 were as follows:

1. **R&amp;D Expenses**: The company incurred $7.87 million in R&amp;D expenses during the quarter.
2. **SG&amp;A Expenses**: There were no reported SG&amp;A (Selling, General, and Administrative) expenses in Q4 2024.
3. **Acquisition-Related Expenses**: The deferred policy acquisition costs related to Verona Pharmaceuticals were not disclosed.

In summary, Verona Pharmaceuticals focused on R&amp;D in Q4 2024, with no reported SG&amp;A expenses, and acquisition-related details were not disclosed.</div> <div class="dialog_answer" data-v-0eba195e=""><div class="dialog_content" data-v-0eba195e=""><div class="answer_content" data-v-0eba195e=""></div></div></div></div></div> </div></div></div> </div> <div class="extra-module" data-v-261d488f=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/recommend-logo.4f9ccc8.png" alt="right-logo" fetchpriority="high" class="recommend-logo-img" data-v-261d488f=""> <div class="recommend-part" data-v-7790c618="" data-v-261d488f=""><div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/screener-recommend-icon.b007ca8.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime finds your next big stock</span></div> </div> <div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/stock-recommend-icon.77f1c78.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime powers your decisions</span></div> </div></div> </div> <div class="container-mask" style="display:none;"></div></div></div></div><script>window.__NUXT__=(function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X,Y,Z,_,$,aa,ab,ac,ad,ae,af,ag,ah){return {layout:"default",data:[{noData:c,currentQuestion:d,textDescription:H,comeFrom:"AInvestShareLink",events:[],answerSource:l}],fetch:{},error:m,state:{sharePreviewModule:{loadJgySuccess:e,dialogRenderList:[{originAnswer:{input_media_info:[],session_round:n,agent_id:a,output_media_info:[],task_id:a,language:a,source:l,cache_builder:a,reply_action:"Answer",execute_mode:w,event_refresh_answer:a,param:"{\"entity_info\":{},\"add_info\":{\"ori_question\":\"How did Verona Pharmaceuticals' expenses trend in Q4 2024?\"},\"event_list\":[],\"client_ip\":\"\",\"question\":\"How did Verona Pharmaceuticals' expenses trend in Q4 2024?\",\"user_id\":\"dp58942139\",\"user_name\":\"\",\"trace_id\":\"7d33de47-7c9d-4e57-9da0-e6f157b52e52\",\"session_id\":\"7d33de47-7c9d-4e57-9da0-e6f157b52e52\",\"source\":\"ths_ainvest_lite_web\",\"input_type\":\"typewrite\"}",agent_info:[{info_type:"query_data",query_type:x,text:"1 results found:\n|stock code|stock name|Last Price|Last Change|R&D Expenses[20241231]|Report End Date|\n|---|---|---|---|---|---|\n|VRNA|Verona Pharma|$68.32|-1.19%|$7.87 million|20241231|\n",query_data:{number:n,title:y,query_type:x,condition:a,model_sql:I,data_ext_params:{merge_repeat:c,expand_index:b,data_add:n,add_index:e}}}],answer_chain_name:J,agent_mode:K,native_answer:a,come_from:a,text_answer:H,trace_id:f,cost:15447,event_names:a,question:d,fallback_type:L,input_type:M,fall_back_reason:{fall_back_type:L,may_fall_back_reason:"UNKNOWN",risk_detail:{matched_words:[]}},session_id:f,first_return_cost:4111,cache_type:"no_cache",question_id:f,transfer_question:d,signal_type:"ON_COMPLETE",start_time:z,remote_svc:l,slots:[],answer_type:w,user_id:s,skill_name:A},renderList:[{type:"base_info",answer_path:"logs\u002FbaseInfo",logs:[],base_info:{trace_id:f,session_id:f,user_id:s,question:d,source:l,raw_question:d,version:"3.4.1",action_name:A,nlu:{entity:[{type:N,value:"VRNA.O",market:"185"},{type:"zhishu",value:"865077.TI",market:"89"}]},output_time:z,deep_research:c,deep_thinking:c,agent_mode:K},extra:{}},{answer_path:h,section:{id:i,info_texts:["Thinking"],show_type:j,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"begin"},logs:[],extra:{is_deep_research:c,deep_thinking:c}},{answer_path:h,section:{id:i,info_texts:["Querying Stock: VRNA R&D Expenses in Q4 2024"],show_type:j,choice:[],result_page:{},tag_info_list:[],is_last:b,status:B},logs:[],extra:{action:C,action_input:y,thought:D}},{answer_path:h,section:{id:i,info_texts:["Querying Stock: VRNA SG&A Expenses in Q4 2024"],show_type:j,choice:[],result_page:{},tag_info_list:[],is_last:b,status:B},logs:[],extra:{action:C,action_input:"VRNA SG&A Expenses in Q4 2024",thought:D}},{answer_path:h,section:{id:i,info_texts:["Querying Stock: VRNA Acquisition Related Expenses in Q4 2024"],show_type:j,choice:[],result_page:{},tag_info_list:[],is_last:b,status:B},logs:[],extra:{action:C,action_input:"VRNA Acquisition Related Expenses in Q4 2024",thought:D}},{answer_path:g,section:{id:O,info_texts:[],show_type:E,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:g,section:{id:O,info_texts:[],show_type:E,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:h,section:{id:i,info_texts:["Generating Answer"],show_type:j,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"ongoing"},logs:[],extra:{}},{answer_path:g,section:{id:t,info_texts:[],show_type:u,voice_txt:"Ver",text_answer:P,rich_text:P,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:g,section:{id:2000,info_texts:[],show_type:u,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{title:y,query_type:x,trace_data:a,index:n,model_sql:I,data_ext_params:{merge_repeat:c,expand_index:b,data_add:n,add_index:e},jump_type:"data_query"}],is_last:b},logs:[],extra:{}},{answer_path:g,section:{id:t,info_texts:[],show_type:u,voice_txt:":\n\n1",text_answer:Q,rich_text:Q,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:g,section:{id:1001,info_texts:[],show_type:"fenshi",choice:[],result_page:{},tag_info_list:[{stock_info:{code:R,market_id:"169",name:"Sweetgreen",domain:N},pos:163,section_id:t,txt:R,jump_type:"pos_fenshi"}],is_last:b},logs:[],extra:{}},{answer_path:g,section:{id:t,info_texts:[],show_type:u,voice_txt:"3",text_answer:S,rich_text:S,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"extraInfo\u002FsourceLink",logs:[],extra:{span_id:a,link_id:a,source:a,link_text:a,link_param:a,link_ids:[]}},{answer_path:h,section:{id:i,info_texts:["Completed"],show_type:j,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"end"},logs:[],extra:{}},{answer_path:"suggest\u002Fquestions",section:{id:10002,info_texts:[],show_type:"result_page",choice:[{display_text:o,query_text:o,trace_info:{item_id:"87ebc0a0219eb1d4b3ca9e08208c5a08",item_type:k,item_name:o,rec_info:T}},{display_text:p,query_text:p,trace_info:{item_id:"94a46008b24d0d69fcb1af98c0adbd22",item_type:k,item_name:p,rec_info:U}},{display_text:q,query_text:q,trace_info:{item_id:"025b61a2774101aab090fa0c4140bb25",item_type:k,item_name:q,rec_info:V}}],result_page:{components:[{show_type:"lowcode",title_config:{show_type:"title1",data:{h1:a,h2:a},config:{display:c,txt_style:e,type:"1",display2:c,url:a}},request_config:[{source_type:W,related_name:X}],puuid:F,tag:a,category:"custom",uuid:Y}],global:{urp_static_data:[{name:X,value:{status_code:e,columns:[{type:r,index_name:Z,key:Z},{type:r,index_name:_,key:_},{type:r,index_name:$,key:$},{type:r,index_name:aa,key:aa},{type:r,index_name:ab,key:ab}],datas:[{send_text:o,item_type:k,rec_info:T,display_text:o,rec_reason:a},{send_text:p,item_type:k,rec_info:U,display_text:p,rec_reason:a},{send_text:q,item_type:k,rec_info:V,display_text:q,rec_reason:a}],dataSize:W,status_msg:a}}],lowcode_type:"shunda",interface_request_list:[],lowcode_json:{stack:c,visible:b,childLimit:9999,label:ac,type:"thslc\u002Fthslc-common-container",leaf:c,animate:[],version:"1.0.1",script:[],props:[],path:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fkernel-thslc-resource\u002Fresource\u002Fainvest\u002F0Ae514cfA4\u002Fjs\u002F_thslc-common-container_1.0.1_index.js",isTransparent:b,style:{"background-color":a,"box-shadow":"0px 0px 0px",color:a,width:v,"min-height":"100%",position:ad,height:v},isMaterial:c,id:ac,needTheme:c,hasEditor:c,packed:c,events:[],child:[{readmeUrl:"https:",stack:c,visible:b,customStyle:a,childLimit:e,label:"路径推荐",type:"iwencai\u002FrecommendList",leaf:b,version:"1.12.0",animate:[],url:G,componentUuid:Y,script:[{name:ae,id:20240320,content:"return {\r\n  created: function created() {\r\n    this.isActive = !Boolean(this.$parent.$parent.$parent.$parent.$parent.$parent.question);\r\n    var showId ='tkPanel_bottomTag';\r\n  this.buryPointId = showId;\r\n  }\r\n};"}],props:{recommendList:[],isTransparent:b,renderType:"blue"},path:G,meta:{custom_editor_url:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0editor.js",js_url:G},style:{"background-color":a,margin:"-12px 0px -12px 0px",color:a,display:"block",width:v,position:ad,height:v},isMaterial:b,_id:19,id:ae,hasEditor:b,packed:c,events:[],isSetDefaultValue:b}]}},page:{layout:{layout_data:"[{\"uuid\":\"ztxxx06c0a024223920bbbeb1e0926\",\"showType\":\"lowcode\",\"children\":[]}]"},render_for:af,voice_txt:a,tracking_info:{},uuid:F},order:{is_auto:c,render_for:af,chart_type:"command",puuid:F}},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"suggest\u002Finputs",section:{id:10000,info_texts:[],show_type:"choice",choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"logs\u002Ftrace_debug",section:{id:1003,info_texts:[],show_type:E,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{action_name:A,with_paid_index:c,no_refresh_answer:c,answer_source:{agent_id:a,agent_name:a,execute_mode:w,answer_chain_name:J},is_deep_research:c,deep_thinking:c,create_time:1746720665196},is_last:b}],questionItem:{data:{qStr:d,encodeFlag:c,imageData:m,docsData:[],quoteData:m},tplType:"question"},events:ag,agentId:a,param:{entity_info:{},add_info:{ori_question:d},event_list:ag,client_ip:a,question:d,user_id:s,user_name:a,trace_id:f,session_id:f,source:l,input_type:M}}],userId:s,userName:a,startTime:z,mobileType:a,comeFrom:a,textConstants:{},dialogContainer:m,endSignal:c,theme:"white",showTracePopup:c,traceListData:[],chatTraceTargetIndex:e,traceTableData:m,showMask:c}},serverRendered:b,routePath:"\u002Faime\u002Fshare\u002Fhow-did-verona-pharmaceuticals-expenses-trend-in-q4-2024-9772b5\u002F",config:{_app:{basePath:ah,assetsPath:ah,cdnURL:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fiwc-aime-seo\u002F"}}}}("",true,false,"How did Verona Pharmaceuticals' expenses trend in Q4 2024?",0,"7d33de47-7c9d-4e57-9da0-e6f157b52e52","other\u002FopenAnswer","progress\u002Fsearching_for",1000,"searching_for","llm_generated","ths_ainvest_lite_web",null,1,"What were Verona Pharmaceuticals' total expenses in Q4 2024?","What was the breakdown of Verona Pharmaceuticals' Q4 2024 expenses by category?","How did Verona Pharmaceuticals' Q4 2024 expenses impact its overall profitability?","STR","dp58942139",2001,"rich_text","auto","agent","intusstock","VRNA R&D Expenses in Q4 2024",1746720649749,"inspect stocks","thinking","Querying Stock","The user seeks to analyze Verona Pharmaceuticals' (VRNA) Q4 2024 expenses. I should focus on VRNA’s Q4 2024 R&D, SG&A, and acquisition-related expenses. I will use FinQuery for the data mentioned above.","signal","39196","\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0index.js","Verona Pharmaceuticals' expenses in Q4 2024 were as follows:\n\n1. **R&D Expenses**: The company incurred $7.87 million in R&D expenses during the quarter.\n2. **SG&A Expenses**: There were no reported SG&A (Selling, General, and Administrative) expenses in Q4 2024.\n3. **Acquisition-Related Expenses**: The deferred policy acquisition costs related to Verona Pharmaceuticals were not disclosed.\n\nIn summary, Verona Pharmaceuticals focused on R&D in Q4 2024, with no reported SG&A expenses, and acquisition-related details were not disclosed.","select   stock_code,   r_d_expenses from   ustock_fin_data where   report_end_date = date('2024y4q')   and stock_code = 'VRNA.O'","agent_common_v2\nagent-summary","normal_agent","NONE","typewrite","stock",999,"Verona Pharmaceuticals' expenses in Q4 2024 were as follows[^1]",":\n\n1. **R&D Expenses**: The company incurred $7.87 million in R&D expenses during the quarter.\n2. **SG&A Expenses**: There were no reported SG&A (Selling, General, and Administrative) expenses in Q4 2024.\n","SG","3. **Acquisition-Related Expenses**: The deferred policy acquisition costs related to Verona Pharmaceuticals were not disclosed.\n\nIn summary, Verona Pharmaceuticals focused on R&D in Q4 2024, with no reported SG&A expenses, and acquisition-related details were not disclosed.","2+679_496_21_554+0+0+7d33de47-7c9d-4e57-9da0-e6f157b52e52+87ebc0a0219eb1d4b3ca9e08208c5a08+llm_generated+aimeTagAnalysis+0+0.01986001431941986+1","2+679_496_21_554+0+0+7d33de47-7c9d-4e57-9da0-e6f157b52e52+94a46008b24d0d69fcb1af98c0adbd22+llm_generated+aimeTagAnalysis+0+0.011646762490272522+2","2+679_496_21_554+0+0+7d33de47-7c9d-4e57-9da0-e6f157b52e52+025b61a2774101aab090fa0c4140bb25+llm_generated+aimeTagAnalysis+0+0.004643152467906475+3",3,"recommend_query_list","ztxxx06c0a024223920bbbeb1e0926","send_text","item_type","rec_info","display_text","rec_reason","root","relative","iwencai\u002FrecommendList0326","aigc",Array(0),"\u002F"));</script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/b929a16.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/28ccbec.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/d9802b5.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/2077034.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/1e0f8d6.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/7a5f495.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/921844b.js" defer=""></script>